- Have any questions?
- contact@iteronco.com
Current therapeutic strategies for solid tumors are limited by the physical and structural barriers of the tumor microenvironment. While most efforts focus on enhancing the potency of therapeutic agents, IterOnco addresses a complementary and critical challenge: making the tumor itself more accessible to treatment.
Itero-101 is a repositioned molecule being developed to transiently remodel key components of the tumor microenvironment. Administered upstream of treatment, it is designed to create conditions more favorable to therapeutic access — starting with immune cell penetration, with broader combinatorial potential across treatment modalities.
As a repositioned molecule, Itero-101 benefits from existing safety, manufacturing, and regulatory data, enabling a significantly accelerated and de-risked development pathway compared to de novo drug development. The intellectual property covering its oncology applications is protected by a priority patent filed in 2025 and extended internationally via PCT.
In preclinical tumor models, Itero-101 administration has been associated with:
These results were obtained in a murine model of pancreatic ductal adenocarcinoma, establishing proof of concept for the microenvironment-first approach. Further mechanistic and pharmacological studies are ongoing.
This technology is currently in an exploratory proof-of-concept phase, developed in partnership with a leading French academic laboratory. The program targets:
Results from this program are expected to support future clinical development and may be the subject of additional intellectual property filings.
Effective immune cell therapy requires not only access to the tumor, but also sufficient quantities of highly functional immune cells. Current NK cell expansion methods face significant limitations: long production times, variable yields, and high manufacturing costs.
IterOnco is developing, in collaboration with academic partners, a proprietary technology for the ex vivo expansion of natural killer (NK) cells. This platform aims to produce large quantities of functional NK cells with improved consistency, reduced production timelines, and lower costs — enabling a true “off-the-shelf” approach to NK cell therapy.
Together, these two platforms form the foundation of IterOnco’s therapeutic strategy. In our lead program, Itero-101 prepares the tumor and optimized NK cells deliver the immune response. This sequential combination approach is designed to maximize therapeutic efficacy in solid tumors where current treatments fail.
Looking ahead, the tumor-remodeling properties of Itero-101 are not limited to immunotherapy. By improving vascular function and reducing structural barriers, Itero-101 has the potential to enhance the delivery and efficacy of a broad range of therapeutic agents — including chemotherapy, antibody-drug conjugates, and targeted therapies — opening significant opportunities for future combination strategies across different types of solid tumors.